POLB-001
Product
by Poolbeg Pharma plc
POLB-001 is an investigational oral immunomodulator and p38 MAP kinase inhibitor being developed to prevent or reduce cytokine release syndrome (CRS), a potentially life-threatening inflammatory reaction associated with cancer immunotherapies. The candidate is intended to make these treatments safer and potentially enable their administration in a broader range of healthcare settings.
What experts have said about POLB-001
3 statements · 3 positive
Poolbeg aims to enroll approximately 30 patients in its POLB-001 trial.
“our ultimate goal is to kind of build this up to roughly or approximately 30 patients”
Open the episode · S11 Ep93: The Sunday Roast, Mid-Summer Special featuring African Pioneer, Poolbeg Pharma, Technology Minerals, Talon Resources and Ajax Resources plc #AFP #POLB #TM1 #TAR #AJAXListen at 35:23
Poolbeg expects trial data to enable partnering of POLB-001.
“we believe that we'll be able to partner the program because we've started really productive discussions”
Open the episode · S11 Ep93: The Sunday Roast, Mid-Summer Special featuring African Pioneer, Poolbeg Pharma, Technology Minerals, Talon Resources and Ajax Resources plc #AFP #POLB #TM1 #TAR #AJAXListen at 35:30
Poolbeg expects POLB-001 to reduce or eliminate cytokine release syndrome.
“we're going to reduce or eliminate CRS”
Open the episode · S11 Ep93: The Sunday Roast, Mid-Summer Special featuring African Pioneer, Poolbeg Pharma, Technology Minerals, Talon Resources and Ajax Resources plc #AFP #POLB #TM1 #TAR #AJAXListen at 48:47
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
2 episodes featuring POLB-001
The Sunday Roast
Mining deals and biotech catalysts shape a midsummer market review
The episode tests how financing, clinical evidence, national resilience and exploration milestones could reshape several small-cap stories through 2026.
Aug 2, 2026 · 1h 45m
The Sunday Roast
Small caps rally as AI valuations and mineral projects face scrutiny
The episode connects renewed UK small-cap optimism with the valuation, funding and development risks shaping resource and technology investments.
May 24, 2026 · 1h 17m